Qurient Co

Qurient Co Equity

The The Equity of Qurient Co (115180.KQ) as of Nov 5, 2026 is 34.04 B KRW. In the previous year, The Equity was 57.60 B KRW — a change of -40.90% (lower).

Equity

34.04 BKRW

YoY

-40.90%

Last updated:

In 2025, Qurient Co's equity was 34.04 B KRW, a -40.90% increase from the 57.60 B KRW equity in the previous year.

The Qurient Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
39.41 B KRW
Jan 1, 2019
17.38 B KRW
Jan 1, 2020
56.57 B KRW
Jan 1, 2021
51.59 B KRW
Jan 1, 2022
30.95 B KRW
Jan 1, 2023
46.62 B KRW
Jan 1, 2024
57.60 B KRW
Jan 1, 2025
34.04 B KRW
The Qurient Co Equity history
YEAREquityYoY
34.04 BKRW-40.90%
57.60 BKRW+23.55%
46.62 BKRW+50.61%
30.95 BKRW-40.01%
51.59 BKRW-8.79%
56.57 BKRW+225.50%
17.38 BKRW-55.90%
39.41 BKRW+171.15%
14.53 BKRW-40.31%
24.35 BKRW+741.35%
2.89 BKRW-113.35%
-21.68 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Qurient Co's Equity

Qurient Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Qurient Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Qurient Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Qurient Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Qurient Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Qurient Co stock

The Equity of Qurient Co is 34.04 B KRW in 2025.

The Equity of Qurient Co changed from 57.60 B KRW to 34.04 B KRW, representing a -40.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Qurient Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Qurient Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Qurient Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Qurient Co